Cordula Zeller
Binger Str. 173
Ingelheim Am Rhein, RP 55216, Germany
Ingelheim Am Rhein, RP 55216, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Implantable Cardioverter-Defibrillator Therapy in Contemporary Heart Failure Patients: An Analysis From the EMPEROR-Reduced Trial.
Journal: JACC. Heart failure
Published: October 05, 2025
Proteomic patterns according to ejection fraction: an EMPEROR-programme analysis.
Journal: European journal of heart failure
Published: July 24, 2025
Patient-Reported Outcomes as End Points in Heart Failure Trials.
Journal: Circulation
Published: April 14, 2025
Competing Risks in Clinical Trials: Do They Matter and How Should We Account for Them?
Journal: Journal of the American College of Cardiology
Published: April 17, 2024
Recurrent Events in Cardiovascular Trials: JACC State-of-the-Art Review.
Journal: Journal of the American College of Cardiology
Published: June 20, 2023
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause.
Journal: Journal of the American Heart Association
Published: December 24, 2022
The win ratio method in heart failure trials: lessons learnt from EMPULSE.
Journal: European journal of heart failure
Published: December 05, 2022
Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions.
Journal: European journal of heart failure
Published: May 03, 2022
Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF.
Journal: JACC. Heart failure
Published: December 08, 2021
Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
Journal: Journal of the American College of Cardiology
Published: December 06, 2021
Last Updated: 09/26/2026